Comparison
Omega-3 (DHA/EPA) vs CBD (Cannabidiol)
Omega-3 (DHA/EPA)
Essential fatty acids critical for brain structure and function. DHA comprises ~40% of brain polyunsaturated fatty acids.
CBD (Cannabidiol)
Non-psychoactive cannabinoid from hemp. Anxiolytic, anti-seizure, anti-inflammatory. The supplement market has grown explosively despite mixed evidence base.
| Field | Omega-3 (DHA/EPA) | CBD (Cannabidiol) |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 1000–3000mg | 25–600mg |
| Half-life | 24h | — |
| Onset | — | — |
| Evidence | EVIDENCEA | EVIDENCEB |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USOTC | USOTC |
| PubMed refs | 5200 | 6800 |
The comparison in plain English
Auto-generated from dataOmega-3 (DHA/EPA) and CBD (Cannabidiol) are both in the neuroprotective category respectively. Omega-3 (DHA/EPA) Essential fatty acids critical for brain structure and function. CBD (Cannabidiol) Non-psychoactive cannabinoid from hemp.
Bottom line
Omega-3 (DHA/EPA) (evidence A, safety 5/5) has a weaker evidence base than CBD (Cannabidiol) (evidence B, safety 4/5). Omega-3 (DHA/EPA) has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Omega-3 (DHA/EPA) if
Omega-3 (DHA/EPA) is the better fit when your goal aligns with its mechanism (DHA (docosahexaenoic acid) is a structural component of neuronal cell membranes, maintaining fluidity and supporting receptor function) and the dose range (1000–3000mg) suits your protocol. Half-life is 24h.
Choose CBD (Cannabidiol) if
CBD (Cannabidiol) is the better fit when your goal aligns with its mechanism (Modulates the endocannabinoid system through indirect mechanisms — CBD doesn't bind CB1 or CB2 receptors directly like THC does) and the dose range (25–600mg) suits your protocol. Half-life is —h.